Bioactivity screening of marine cyanobacteria for the isolation of novel compounds for hepatic steatosis and diabetes
-
1
Centro Interdisciplinar de Pesquisa Marine e Ambiental (CIIMAR), Portugal
-
2
Faculdade de Ciências, Universidade do Porto, Portugal
Introduction: Obesity and obesity-related co-morbidities diseases (especially nonalcoholic fatty liver disease and diabetes) have deep negative effects and therapeutics has been widely study. Cyanobacteria, known as blue-green algae, are recognized to produce many secondary metabolites including toxins, with applications to the pharmaceutical industry. The aim of this study is to investigate the effect of extracts from cyanobacteria to reduce lipid accumulation in a model of hepatic steatosis, and the increase of glucose uptake after starving conditions using HepG2 cells in vitro.
Material and methods: HepG2 cells were treated with oleic acid (OA) to induce lipid accumulation and co-exposed to cyanobacterial extracts. Lipid levels were quantified by Nile red in a fluorescence plate reader. Subsequently, sulforhodamine B (SRB) assay was performed to analyze viability. For glucose uptake, cells were starved in Hank’s Balanced Salt Solution and then exposed to cyanobacterial extracts. Glucose uptake was quantified by 2-NBDG. Subsequently, MTT assay was performed to measure the cytotoxicity. Extraction and production of fractions of cyanobacterial biomass was performed with hexane, ethyl acetate and methanol, either in a polarity gradient extraction or in a sequential extraction.
Results and conclusions: Two assays were optimized in HepG2 cells, one to quantify the reduction of lipid accumulation and other one to quantify the increase of glucose uptake. Model compounds reduced the lipid level and increased the glucose uptake, as shown in the literature. Extracts from cyanobacteria strains were tested and positive bioactivities were obtained in some fractions from different cyanobacterial strains. In the ongoing work, we intend to isolate novel bioactive compounds and to elucidate their structures.
Acknowledgements
This work was supported by the European ERA-NET Marine Biotechnology project CYANOBESITY (ERA-MBT/0001/2015), financed by national funds through FCT (Fundação para a Ciênca e a Tecnologia, Portugal).
Keywords:
Hepatic Steatosis,
Diabetes Mellitus, Type 2,
Cyanobacteria,
HepG2 cells,
bioactive compounds
Conference:
IMMR'18 | International Meeting on Marine Research 2018, Peniche, Portugal, 5 Jul - 6 Jul, 2018.
Presentation Type:
Poster Presentation
Topic:
Blue Biotech
Citation:
Rosa
F,
Ribeiro
T,
Urbatzka
R and
Vasconcelos
V
(2019). Bioactivity screening of marine cyanobacteria for the isolation of novel compounds for hepatic steatosis and diabetes
.
Front. Mar. Sci.
Conference Abstract:
IMMR'18 | International Meeting on Marine Research 2018.
doi: 10.3389/conf.FMARS.2018.06.00065
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
06 May 2018;
Published Online:
07 Jan 2019.
*
Correspondence:
Dr. Ralph Urbatzka, Centro Interdisciplinar de Pesquisa Marine e Ambiental (CIIMAR), Matosinhos, Portugal, ralph.urbatzka.ciimar@gmail.com